Gossamer Bio, Inc. GOSS
9.03 USD -0.42 (-4.44%)
Nov 3, 2026, 3:30 PM EST
8.80 Day range 9.68
8.29 52-week range 309.60
- YTD
- -96.36%
- 1 year
- -95.28%
- Market cap
- 55.45M
- Revenue (ttm)
- 53.29M
- Profit margin
- -235.00%
- EPS (ttm)
- -52.80
- Shares out
- 488.85M
- Forward P/E
- -0.69
- YTD return
- -96.36%
- 1-year return
- -95.28%
- Volume
- 94.61K
- Avg volume
- 258.77K
- Open
- 9.38
- Previous close
- 9.45
- Day's range
- 8.80 – 9.68
- 52-week range
- 8.29 – 309.60
- Beta
- 2.00
- Price target
- 132.48 (+1367.1%)
- Earnings date
- Nov 4, 2026
1m -0.28 (-2.99%)
Key statistics
- Enterprise value
- 52.65M
- PEG ratio
- 0.00
- Price / sales
- 98.44
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -19.60%
- Free cash flow
- -29.76M
- Total cash
- 57.03M
- Total debt
- 40.07M
- Return on equity
- 0.00%
- Short % of float
- 0.21%
- 50-day average
- 13.50
- 200-day average
- 78.36
Analyst view
Price target (mean) 132.48 +1367.1% upside
Now 9.03
- Target (low)
- 22.40
- Target (mean)
- 132.48
- Target (high)
- 320.00
Ratings (0m) 7 3 buy · 3 hold · 1 sell
- Strong buy1
- Buy2
- Hold3
- Sell0
- Strong sell1
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -3.89.
Financials — quick view
GOSS Revenue — quarterly 9.24M
GOSS Net income — quarterly 16.90M
GOSS EPS — quarterly 4.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -3.69 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -9.87 | -0.20 | +9.67 | +97.97% |
| May 18, 2026 | Mar 31, 2026 | -13.60 | -0.20 | +13.40 | +98.53% |
| Mar 18, 2026 | Dec 31, 2025 | -16.00 | -0.21 | +15.79 | +98.69% |
| Nov 6, 2025 | Sep 30, 2025 | -15.20 | -16.80 | -1.60 | -10.53% |
| Aug 11, 2025 | Jun 30, 2025 | -14.40 | -0.17 | +14.23 | +98.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | Piper Sandler | main | Overweight | Overweight |
| Jul 28, 2026 | Leerink Partners | up | Market Perform | Outperform |
| Jul 27, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| May 26, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 19, 2026 | Barclays | main | Underweight | Underweight |
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gossamerbio.com
News
Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160 
Corient Private Wealth LP Purchases 1,647,315 Shares of Gossamer Bio, Inc. $GOSS 
12 Health Care Stocks Moving In Friday's After-Market Session 
Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial Hypertension 
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension - HC Wainwright & Co. Maintains Buy on Gossamer Bio, Raises Price Target to $90
12 Health Care Stocks Moving In Friday's After-Market Session 
Hsbc Holdings PLC Increases Stock Position in Gossamer Bio, Inc. $GOSS 
Gossamer Bio Appoints Greg Ciongoli to Board of Directors 
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Your note
Sign in to keep a note on GOSS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARANDA RICHARD | Officer | Stock Award(Grant) | Jan 1, 2026 | 465,645 |
| CHRISTIAN WAAGE | Officer | Stock Award(Grant) | Jan 1, 2026 | 882,175 |
| GIRAUDO BRYAN M. | Chief Operating Officer | Stock Award(Grant) | Jan 1, 2026 | 869,747 |
| HASNAIN FAHEEM | Chief Executive Officer | Stock Award(Grant) | Jan 1, 2026 | 6,245,870 |
| MILLIGAN SANDRA | Director | Purchase | Aug 18, 2025 | 58,050 |
| PETERSON CARYN | Officer | Stock Award(Grant) | Jan 1, 2026 | 259,333 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Shaw D.E. & Co., Inc. | 8.38% | 40,959,285 | 439.49M | Jun 29, 2026 |
| 683 Capital Management LLC | 8.02% | 39,198,868 | 420.60M | Jun 29, 2026 |
| DeepCurrents Investment Group, LLC | 7.70% | 37,665,073 | 404.15M | Jun 29, 2026 |
| Context Capital Management, LLC | 5.92% | 28,946,459 | 310.60M | Jun 29, 2026 |
| Worth Venture Partners, Llc | 5.12% | 25,017,881 | 268.44M | Jun 29, 2026 |
| AQR Capital Management, LLC | 3.20% | 15,629,993 | 167.71M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.41% | 6,910,934 | 74.15M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.46% | 2,243,305 | 24.07M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.31% | 1,501,116 | 16.11M | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 0.20% | 986,826 | 10.59M | May 30, 2026 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 0.20% | 977,030 | 10.48M | May 30, 2026 |
| VANGUARD WORLD FUND-Vanguard Health Care Index Fund | 0.11% | 541,950 | 5.82M | May 30, 2026 |